Background The Ad26.COV2.S vaccine, which was approved as a single-shot immunization
regimen, has been shown to be effective against severe coronavirus disease 2019. …

Background During the COVID-19 pandemic, the scarcity of resources has necessitated
triage of critical care for patients with the disease. In patients aged 65 years and older, triage …

Background Bivalent mRNA-based COVID-19 vaccines encoding the ancestral and omicron
spike (S) protein were developed as a countermeasure against antigenically distinct SARS-…

Background and Aims Patients with established coronary artery disease (CAD) are likely to
receive a combination of aspirin, a statin, and blood pressure (BP)–lowering agents. …

Currently, four COVID-19 vaccines are authorized for use in the European Union by the
European Medicines Agency (EMA), ie, Ad26. COV2. S (1), ChAdOx1 nCoV-19 (2), mRNA1273 (…

Waning antibody responses after COVID-19 vaccination combined with the emergence of the
SARS-CoV-2 Omicron lineage led to reduced vaccine effectiveness. As a countermeasure, …

The emergence of SARS-CoV-2 variants raised questions regarding the durability of immune
responses after homologous or heterologous boosters after Ad26.COV2.S-priming. We …

Aims Cardiovascular fixed-dose combination pills, or polypills, may help address the
widespread lack of access and adherence to proven medicines. Initiation of polypill-based care …

The emergence of novel SARS-CoV-2 variants led to the recommendation of booster
vaccinations after Ad26.COV2.S priming. It was previously shown that heterologous booster …

Vaccination against coronavirus disease 2019 (COVID-19) has contributed greatly to providing
protection against severe disease, thereby reducing hospital admissions and deaths. …